examples of founding and evolving leading lifescience...

Examples of founding and evolving leading LifeScience companies

November 2016

2 IDEAHUB TRILAGO| November 2016 |

Peter Pohl

Born: in Salzburg

Love: my wife and my two children (age 9&7)

Education: Business Adminstration

Serial entrepreneur

Passion: Founding of companies, growth of

companies, leadership, consultancy

Place of Living: The Bodensee


The beginning


Foto Hinterhof Fritz-Arnold-Strasse


GATC Headquarter Konstanz


GATC Biotech – Innovation management throughout the years

New technologies allow better insights and deeper understanding of scientific requirements.

World’s first non-radioactive sequencing technology

Today

1st NGS service provider

Multiplatform (PacBio + HiSeq + MiSeq)

Realisation of personalised medicine

GATC-BöxleTM

1st 24h sequencing service

GATCLIQUIDTM


Online platform

1 2 3 4 5 6 7

All tubes/plates carry barcode labels

Efficient logistic solutions

Automated production processes

Sequencing, assembly & analysis

Data delivery via secured myGATC account

Customer Hotline; NextGen projects supervised by project management

Our service workflow enables high-quality research


Production: The power horses at GATC

European Custom Sequencing Center, Cologne, Germany

Genome and Diagnostic Centre, Constance, Germany

Fastest Sanger sequencing service in Europe

ISO 17025 accredited Swift logistics Overnight service

~2.500.000 samples p.a.

Next-generation sequencing on all prevalent technologies

INVIEW – standardised NGS ISO 17025 / ISO 13485 Certified Service Provider of Illumina and PacBio

~50.000 samples p.a.


We have subsidiaries, labs and sales offices in…

… Germany (incl. Labs)

… Great Britain

… France

… Sweden

… and customers in over 30 countries

European wide sales and production

structure


Product Portfolio: GATC Sequencing Solutions overview

Pre-Sequencing

LIFE TECHNOLOGIES Pacific Bioscience

Illumina

HUMAN EXOME AMPLICON TRANSCRIPTOME EPIGENOME MODIFICATION ANALYSIS DE NOVO GENOME MICROBIOME

Flexibility in services, delivery times and batch size NightXpressTM

Tubes or 96-well format

Library

Sequencing

Bio-IT

Sanger sequencing Next Generation Sequencing


Uniqueness of GATC Biotech

GATC is the No. 1 Service Provider of DNA and RNA sequencing in Europe since 25 years

Family owned business in the molecular diagnostics area

Experience and loyalty of Management

Excellent network in the academic and medical space with more then 10.000 customers

High reputation and strong, well-known brand

GATC runs a profitable core business with strong upside opportunities in molecular diagnostics

First-Mover experience (new technologies, LifeCodexx, Liquid Biopsy)

Successful entry in the diagnostics market with LifeCodexx

Scaling and optimizing processes in the molecular biology area

Patents and proprietary processes & algorithms (GATC-LIMS, PraenaTest, PraenaBoxx)

Accreditated processes with ISO 17025, ISO 13485, ISO 9001; Certified Service Provider of Agilent, Illumina and Pacific Biosciences; potential CAP/CLIA accreditation

GATCLIQUID The Liquid Biopsy Service Line of GATC


Limitations of tissue biopsy

Biopsy is invasive May not be feasible based on patient condition or tumour accessibility

Impractical for periodic monitoring for progression recurrence

Biopsy tissue is often very limited Greater demand due to molecular profiling

Surgery is costly

Example Cancer: heterogeneous disease Molecular properties differ within tumours

Therapy causes changes in tumour cells


The principle of liquid biopsy


Liquid Biopsy – The X-Ray of the 21st century

Liquid Biopsy is non-invasive – declining need for operations for diagnostic purpose

Body fluids are easier and less costly to collect compared to solid biopsies

Growing interest in research brings Liquid Biopsy in clinical environment

Liquid biopsies have the potential to replace traditional invasive diagnostics methods that are often ineffective or nearly impossible to perform. By improving the outcome for cancer patients, liquid biopsy can ultimately become the X-ray of the 21st century.


GATCLIQUID: GATC’s research services for cancer research and diagnosis

Unbiased discovery

Exome sequencing of matched samples from tumour tissue, cell-free DNA and blood

ONCOEXOME

Targeted screening

Panel sequencing of clinically actionable mutations, including low frequency mutations

ONCOPANEL

Monitoring

Frequent detection of single driver mutations after treatment, such as surgery or therapy

ONCOTARGET


GATCLIQUID services follows the cancer treatment timeline

Screening Diagnosis Follow-up Treatment

STAGING SURGERY | CHEMO | RADIATION RECUPERATION

Biopsy Imaging Tumour size Molecular stratification

Tumour removal Irradiance Medication

Monitoring

Diagnosis

Adjuvant treatment decision Companion diagnostics Measurement of therapeutic response Follow-up

GATCLIQUID ONCOEXOME

ONCOPANEL

ONCOTARGET

19

Market Opportunity Non-invasive prenatal testing (NIPT) is the safest and most accurate option to test for genetic abnormalities during pregnancy

20

First NIPT to enter the European market when it was launched in August 2012 following clinical validation

Originally (at launch) focused on the detection of fetal trisomy T21; test capabilities have since been extended to detect T13, T18,

gonosomal aneuploides and multiple pregnancies

• Only NIPT in Europe for the detection of the indicators listed above that is performed in accordance with the In-Vitro Diagnostics Directive

98/79/EG of the European Union (requires both CE-marked analysis software and a full quality assurance system)

Utilizes Massively Parallel Sequencing (MPS), which is typically accepted as one of the best validated methods for NIPT

PrenaTest® NGS NIPT for detection of fetal trisomies T21, T13, T18 and more

Currently available in 35 countries across Europe, the Middle East and Asia

• Currently holds either the number one or two market position in all active territories

• Recently launched in Italy, Belgium, Serbia, Slovenia, Croatia, Macedonia, Montenegro,

Ukraine, Greece, Portugal with ongoing launches in Russia, India, Vietnam and Spain

Analysis includes the use of both LifeCodexx’ proprietary QuantYfeX® assay (for

quantification of fetal DNA at the beginning of the analysis) and PrenaTest®

DAP.plus analysis software (for bioinformatic analysis of the sequencing data)

Applied for reimbursement in Germany and Switzerland submitted in 2013 and in

Hungary in 2015; received statutory reimbursement in Switzerland in 2015 and

Germany and Hungary are pending

Initiated a Post Marketing Clinical Follow-Up (PMCF) study with the University of

Bonn in Germany; aim is to determine the birth outcome of ~2,000 patients - more

than 1,500 patients recruited to date


Challenges during Founding & Evolving

Get the product

DBE / Services / PrenaTest

Get the investment

Own money

Customer

Public funds

Other people´s money („OPM“): VC / PE / Family Office / F&F

Get the right team

More important than product and money!!

Get the customer

…the only one that brings in money (if you want to earn money)

Get the grip

Think first… and then move, move, move

Move the bottlenecks

…or they will move you…


Thank you!

examples of founding and evolving leading lifescience...

Documents